High spending on prescription drugs with both orphan and non-orphan indications suggest potential misuse of Orphan Drug Act designations.
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. WHAT IS WHITE BAGGING… There’s a lot of jargon in
PBMs leverage competition between drugs to create savings for patients.
Dr. Lawton Burns Says PBMs are Unfairly Blamed for High Drug Prices, Should Look At Big Drug Companies In case you missed it, Lawton R. Burns, PhD, professor of health care management at the Wharton School of the University of
The independent pharmacy lobby is urging state legislatures to enact new legislation targeting pharmacy benefit managers (PBMs) that would increase fees and/or add surcharges to transactions with pharmacies. This is based upon two arguments: 1) that independent pharmacies are becoming
Conversation on “Improving Competition to Lower Drug Prices” Emphasizes Need to Stop Abuse of the Patent System Last week, The Hill hosted an event titled, “Prescription for Change: Improving Competition to Lower Drug Prices.” During the event, lawmakers and a panel of drug
Welcome to the Pharmacy Benefit Brief. This brief is your monthly snapshot of news from America’s prescription drug supply chain including pharmacy benefit managers, independent pharmacies, and drug manufacturers. It’s a Dog Eat Dog World… As a
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) released the following statement on new National Health Expenditure (NHE) data from the Centers for Medicare & Medicaid Services: The latest NHE survey shows that the retail prescription drug net price index declined
New Research Paper Demonstrates Declining Biosimilars Prices and Increasing Health Plan Coverage (Washington, D.C.) — Pharmacy benefit managers, PBMs, support the proliferation and use of biosimilars. A robust biosimilar market will increase competition for biologic drugs and provide added choice
Patent thickets are a drug manufacturer’s strategy that keeps competitor products off the market and reduces PBMs’ ability to negotiate savings.
©2024 PCMA. All Rights Reserved.
